Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul;1(1):14-22.
doi: 10.1111/j.1753-5174.2007.00003.x.

Effects of C-reactive Protein and Homocysteine on Cytokine Production: Modulation by Pravastatin

Effects of C-reactive Protein and Homocysteine on Cytokine Production: Modulation by Pravastatin

Yu Asanuma et al. Arch Drug Inf. 2008 Jul.

Abstract

OBJECTIVE: C-reactive protein (CRP) and homocysteine are markers of cardiovascular risk that may have inflammatory effects. HMG coenzyme A reductase inhibitors (statins) have anti-inflammatory effects in vitro, but it is not clear if such responses in vivo are secondary to lipid lowering. We examined the hypothesis that CRP and homocysteine would stimulate cytokine release in human whole blood and that short-term treatment with a statin would inhibit it. METHODS: The time course of IL-6 and MCP-1 production was determined in whole blood incubated with saline, 1 microg/mL lipopolysaccaride (LPS), 50 and 100 microM/L DL-homocysteine, and 5 microg/mL human recombinant CRP for 24 hours at 37 degrees C under 5% CO(2) atmosphere. Cytokine responses were determined in blood drawn from 15 healthy volunteers before and after administration of pravastatin 40 mg daily for 2 days. RESULTS: Both human recombinant CRP and LPS significantly increased the production of IL-6 and MCP-1 in whole blood samples more than 4-fold (P < 0.001) but homocysteine did not. Oral administration of pravastatin, 40mg daily for 2 days, decreased CRP-stimulated IL-6 production by approximately 20% (P = 0.02) 6 hours after incubation, but did not affect MCP-1 production (P = 0.69). Pravastatin treatment did not affect LPS-stimulated MCP-1 but increased IL-6 modestly. CONCLUSIONS: CRP stimulated the production of the proatherogenic mediators MCP-1 and IL-6 in human whole blood, but homocysteine did not. CRP-stimulated production of IL-6, but not MCP-1, was modestly attenuated by short-term treatment with pravastatin.

PubMed Disclaimer

Figures

Figure 2
Figure 2
Effect of pravastatin on IL-6 production in whole blood during stimulation with 5 g/mL recombinant CRP for 6 hours (n = 15). Administration of pravastatin reduced CRP-stimulated IL-6 production by an average of –20% (P= 0.02).
Figure 1
Figure 1
(a) Time course of IL-6 production in whole blood. (b) Time course of MCP-1 production in whole blood. LPS and recombinant CRP induced IL-6 and MCP-1 release in whole blood culture. Data are expressed as mean ± SEM. *P < 0.001 compared with control (IL-6 and MCP-1 production in unstimulated whole blood).

Similar articles

Cited by

References

    1. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517–27. - PubMed
    1. Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet. 2001;358:946–8. - PubMed
    1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–9. - PubMed
    1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43. - PubMed
    1. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877–81. - PubMed